These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26214805)

  • 21. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
    Limmroth V; Hechenbichler K; Müller C; Schürks M
    J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
    Halpern R; Agarwal S; Dembek C; Borton L; Lopez-Bresnahan M
    Patient Prefer Adherence; 2011 Jan; 5():73-84. PubMed ID: 21423591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
    Degli Esposti L; Piccinni C; Sangiorgi D; Perrone V; Aledda L; Marrosu MG; Lombardo F
    Neurol Sci; 2017 Apr; 38(4):589-594. PubMed ID: 28078563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.
    Mokhber N; Azarpazhooh A; Orouji E; Rao SM; Khorram B; Sahraian MA; Foroghipoor M; Gharavi MM; Kakhi S; Nikkhah K; Azarpazhooh MR
    J Neurol Sci; 2014 Jul; 342(1-2):16-20. PubMed ID: 24841321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.
    Mokhber N; Azarpazhooh A; Orouji E; Khorram B; Modares Gharavi M; Kakhi S; Khallaghi H; Azarpazhooh MR
    Psychiatry Clin Neurosci; 2015 Oct; 69(10):649-57. PubMed ID: 25907350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    BMC Neurol; 2014 Jan; 14():11. PubMed ID: 24423119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
    Lundy J; Craig BM
    Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.
    Munsell M; Frean M; Menzin J; Phillips AL
    Patient Prefer Adherence; 2017; 11():55-62. PubMed ID: 28115831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis.
    Nicholas JA; Edwards NC; Edwards RA; Dellarole A; Grosso M; Phillips AL
    BMC Neurol; 2020 Jul; 20(1):281. PubMed ID: 32664928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment patterns following initiation of generic glatiramer acetate among patients with multiple sclerosis from two large real-world databases in the United States.
    Alexander JK; Ariely R; Wu Y; Hulbert E; Bryant A; Su Z; Vardi M; Kasturi J
    Curr Med Res Opin; 2021 Aug; 37(8):1323-1329. PubMed ID: 34003068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data.
    Moccia M; Affinito G; Capacchione A; Lanzillo R; Carotenuto A; Montella E; Triassi M; Morra VB; Palladino R
    PLoS One; 2021; 16(9):e0258017. PubMed ID: 34587188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term interferon-beta treatment for multiple sclerosis.
    Ruggieri RM; Settipani N; Viviano L; Attanasio M; Giglia L; Almasio P; La Bella V; Piccoli F
    Neurol Sci; 2003 Dec; 24(5):361-4. PubMed ID: 14716534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
    Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
    Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
    Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.